托里帕利马布加化学疗法作为扩展阶段小细胞肺癌的第一线治疗:第3期EXTENTORCH随机临床试验
Ying Cheng1, Wei Zhang2, Lin Wu3
1Department of Oncology, Jilin Cancer Hospital, Changchun, China.
JAMA oncology
|November 14, 2024
概括
将托利帕利马布添加到化疗中显著改善了扩散阶段小细胞肺癌 (ES-SCLC) 患者的无进展生存率和整体生存率. 这种组合为这种具有挑战性的疾病提供了一个新的,安全的治疗选择.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 扩散性小细胞肺癌 (ES-SCLC) 是一个重大的临床挑战,患者的预后不佳.
- 目前对ES-SCLC的第一线治疗有局限性,这凸显了对新型治疗策略的需求.
研究的目的:
- 评估托利帕利马布与埃托波和基化疗 (EP) 结合的疗效和安全性,作为ES-SCLC的第一线治疗.
- 在3期随机临床试验中,将这种组合疗法与安慰剂加EP进行比较.
主要方法:
- 一个多中心,双盲,安慰剂控制的3期随机临床试验 (EXTENTORCH研究) 招募了442名ES-SCLC患者.
- 患者接受了toripalimab加EP或安慰剂加EP,然后进行维持治疗.
- 主要终点包括研究人员评估的无进展生存率 (PFS) 和整体生存率 (OS);通过全外因子测序确定了相关生物标志物.
主要成果:
- 与安慰剂加EP相比,托利帕利马布加EP显著改善了PFS (HR,0.67),并降低了死亡风险 (HR,0.80).
- 托利帕利马布治疗的中位寿命为14.6个月,而安慰剂治疗为13.3个月.
- 特定的遗传生物标志物 (低内异质性,某些类型和基因变异) 与托利帕利马布组的良好结果相关. 安全性概况相似,严重不良事件的发生率相似.
结论:
- 将toripalimab添加到第一线EP化疗中,在ES-SCLC患者的PFS和OS中显示出显著的临床益处.
- 组合疗法表现出可接受的安全性.
- 托里帕利马布加EP为被诊断患有ES-SCLC的患者提供了一个有前途的新治疗方案.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
666
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.5K
相关概念视频
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
